A Clinical Comprehensive Evaluation of Long-Acting GLP-1 Receptor Agonists in Type 2 Diabetes Management
This evaluation identifies semaglutide and dulaglutide as the preferred long-acting GLP-1RAs in China's current therapeutic landscape. The standardized, transparent six-dimensional framework provides a replicable methodology for the comprehensive assessment of chronic disease therapies, supporting rational drug selection and resource allocation.
Authors
- Qiying Chen
- Xi Chen
- Weicheng Lin
- Tianyu Chen
Institutions
- Fujian Medical University (CN)
- Quanzhou Normal University (CN)
- Second Affiliated Hospital of Fujian Medical University (CN)
Publication Details
- Journal
- Diabetes Metabolic Syndrome and Obesity
- Published
- 2026-02-01
- DOI
- https://doi.org/10.2147/dmso.s585436
- Primary Topic
- Diabetes Treatment and Management
- Type
- article
- Field-Weighted Citation Impact
- 0.00
Funders
- Fujian Medical University